Case Comprehensive Cancer Center
This study aims to evaluate how walking stability and the ability to perform daily activities change during cancer treatment, and whether a smartwatch can detect these changes. The goal is to develop proactive, personalized tools that automatically monitor treatment response and predict potential complications. To support future implementation, the study will assess the feasibility of wearing a smartwatch for at least 12 hours per day, using a mobile application, and completing weekly questionnaires among patients with primary osteosarcoma or metastatic bone disease.
Wearable sensors, in the form of direct-to-consumer devices, can provide insight to allow timely, proactive, personalized interventions. Nearly 20 percent of US residents own a smart wearable device such as a FitBit or Apple watch. Increasing accessibility and affordability of wearable technology has also allowed for new possibilities to provide personalized and remote care to patients . In part due to the range of sensors in consumer devices that capture multi-modal information. For example, transdermal optical photoplethysmography provides cardiac and respiratory measurements using non-invas…
Inclusion Criteria: * primary sarcoma or metastatic bone disease of the lower extremities or pelvis. * undergoing evaluation for (or have recently undergone) non-surgical or surgical intervention. * recent history of home ambulation. Exclusion Criteria: * under 18 years of age at the time of study enrolment * inability to comprehend consent form and give informed consent * no access to a smartphone (iOS or Android) to interface with watch application * tattoos located on the skin of the wrist or forearm where the watch will be placed or other skin conditions preventing adequate sensor funct…
Participants will be asked to wear the smartwatch daily, for at least 12 hours per day during the 12-week study period, with breaks to recharge the watch as needed.
Arctuva estimate
Verify or correct the compensation shown for this listing.